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In this letter to the editor, we respond to the recent publication by Philibert et al. Methylation array data can
simultaneously identify individuals and convey protected health information: an unrecognized ethical concern (Clinical
Epigenetics 2014, 6:28). Further discussion of the issues raised by the risk of re-identification of epigenetic methylation
data is needed, and a more nuanced approach should be taken with respect to its implications for data sharing policy
than the one provided.
Keywords: Privacy, Data sharing, Epigenome, PolicyWe welcome the recent publication on the risk of re-
identification of methylation array data by Philibert et al.
[1], as it raises important questions concerning access to
epigenetic data which we are carefully considering as
members of the International Human Epigenome Consor-
tium (IHEC). While sensitive to the importance of protect-
ing research participants’ identifiable health data, we
believe that ultimately the adequate level of protection
should be determined by taking into account the scientific,
social, and policy context and following a thorough risk-
benefit analysis of the research being undertaken. In light
of this, we would like to express certain reservations re-
garding the analysis and findings presented in this paper.
We have some reservations regarding the authors’
statement that ‘there was an erroneous expectation that
anonymized genome-wide genetic data contained within
repositories could not be linked to identifiable individ-
uals’. This assumption, according to the authors, led to
the unsound belief that information contained within
publicly available data cannot be used to both infer dis-
ease status and uniquely identify individuals. While we
agree that the limits of data anonymization are now bet-
ter understood following numerous research papers on
this topic, it should be understood that most of this re-
search refers to hypothetical scenarios leading to assess-
ments of low risk of re-identification [2,3]. Moreover, as* Correspondence: yann.joly@mcgill.ca
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unless otherwise stated.the authors recognize: ‘with the exception of isolated in-
stances, protected information regarding disease status
has not been compromised’. For these reasons, apart from
one instance following a publication by Homer et al. [4],
the scientific and policy community generally has not
chosen to increase the level of protection of genome-wide
genetic data by restricting its access through controlled ac-
cess administrative processes [5].
Furthermore, Philibert et al. limit their study of geno-
type to a single cell type (from peripheral blood). Several
studies have also already identified genetic polymor-
phisms directly affecting methylation data [6,7]. More-
over, the form of re-identification discussed by Philibert
et al. would require the individual’s genetic data, in
which case the information at risk is not the genetic data
but any associated patient or participant information. It
is nevertheless important to consider what additional
health information could be revealed by epigenetic infor-
mation. The ‘imputation of phenotypic data’ from methy-
lomes is valid (replicated) for smoking and blood
methylomes, but for any other trait, we do not currently
have unequivocal evidence of health or exposure data be-
ing easily read from these data. Results shown by Figure
one in Philibert et al. show far from perfect prediction,
even given homogeneous sampling to call differences be-
tween smokers and nonsmokers in a controlled experi-
ment. The result is not unexpected since recent studies
[8] have shown a complex relationship with blood methy-
lation and smoking, where the intensity of exposure is
poorly correlated with most changes and some sites revertis is an Open Access article distributed under the terms of the Creative
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others persist. Similarly, for gene expression datasets, and
using pre-existing genetic and expression data from
matching tissue and processing techniques, individual
genetic variation can be predicted from its impact on gene
expression [9]. Furthermore, blood transcriptomes can re-
flect smoking just as methylomes do [8]. Consequently,
many risks reported by the authors would be comparable
to those for gene expression arrays. In the case of both
methylation and gene expression data, the risk of re-
identification relies on access to the DNA of the research
subject and with such biospecimens many similarly ‘im-
putable’ phenotypes become accessible. We note that
microarray-based techniques are being replaced by next-
generation sequencing methods in large-scale epigenome
mapping efforts such as IHEC, and will likely penetrate to
cohort studies, given the approximately 50-fold higher in-
formation content of next-generation sequencing data as
compared to Illumina 450K methylation variants with
‘high accuracy phenotypic imputation’ that may emerge,
and obviously, this data provides unique challenges re-
garding genotypic data privacy.
Our major point of contention with Philibert et al. con-
cerns their conclusion that a preferred response to their
findings would be that ‘access to genome methylation data
be restricted to institutionally approved investigators who
accede to data agreements prohibiting re-identification’.
Although IHEC is deeply committed to the safeguarding
of sensitive health information, we believe this proposal
is premature and an overreaction for the following rea-
sons: 1. as noted, the data analysis is based on technology
that is being superseded by next-generation sequencing; 2.
the risk of re-identification is remote; 3. the health infor-
mation currently at risk consists of tobacco and alcohol
usage - this information is widely available in medical re-
cords and nonmedical sources; 4. going forward, more
comprehensive measures need to be developed that con-
sider prospective informed consent for this type of re-
search; and 5. the proposal to limit access could add to the
burden of institutional review boards and unnecessarily
impede research.
Ideally, re-identification research should consider not
only the technical potential to achieve re-identification
but also the full spectrum of administrative, legal (which
in the U.S. is not limited to HIPAA), and information
technology measures available to reduce the existing
risk. Once this is done, a careful risk-benefit analysis will
need to be undertaken. In this analysis, the benefit of
broad data sharing to medical research, and sometimes
directly to participants (for example, through return of
clinically significant results), should not be underesti-
mated [10]. While several aspects of the consent process
eventually need to be revisited to be adapted to reflect
current technological and scientific practices, shiftingthe discussion surrounding informed consent from un-
realistic promises of confidentiality protection towards a
greater focus on transparency and clarity regarding the
risk actually incurred by participants in OMICS data
sharing projects would be a useful response for all in-
volved. To better communicate this information to par-
ticipants, it could be worth contrasting the risk incurred
by participants accepting the open release of their gen-
etic expression data to that incurred in everyday life by a
regular Internet user.
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